However, many pre-clinical studies have highlighted the potential for such therapies, and a number of clinical trials are currently evaluating safety and efficacy of anti-IL-6/IL-11/STAT3 agents for the treatment of breast cancer. Here, STAT3 is linked to breast cancer.